Tendly Chat - AI Procurement Intelligence

MRTs Fulda Clinic

Klinikum Fulda gAG·Ref T-590384922·via Bekanntmachungsservice

VALUE

€1K

DEADLINE

Nov 12, 2026

TIME LEFT

32 days

Delivery of perfusors and holders

Amt für Recht, Vergabe und Versicherungen·Ref T-762182584·via Bekanntmachungsservice

VALUE

--

DEADLINE

Nov 16, 2026

TIME LEFT

36 days

First aid emergency equipment (initial and subsequent supply) for the Baden-Württemberg Police

Land Baden-Württemberg vertreten durch das Logistikzentrum Baden-Württemberg·Ref T-1645241769·via Bekanntmachungsservice

VALUE

--

DEADLINE

Nov 17, 2026

TIME LEFT

37 days

Open House Original Discount Contracts 2025-05 - Emtricitabine/Tenofovir disoproxil/Rilpivirine (drug combination)

Techniker Krankenkasse·Ref T-298730733·via Bekanntmachungsservice

VALUE

--

DEADLINE

Nov 30, 2026

TIME LEFT

50 days

Open-House-Biologika-Discount-Contracts 2025-25 - Aflibercept (ATC: S01LA05; Strength: 40 mg/ml)

Techniker Krankenkasse·Ref T-756891869·via Bekanntmachungsservice

VALUE

--

DEADLINE

Nov 30, 2026

TIME LEFT

50 days

Open House Original Discount Contracts 2025-19 - Tafamidis

Techniker Krankenkasse·Ref T-420666615·via Bekanntmachungsservice

VALUE

--

DEADLINE

Nov 30, 2026

TIME LEFT

50 days

Open house drug discount contracts for the active ingredient Dimethyl Fumarate, ATC L04AX07

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Ref T-638049579·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jan 31, 2027

TIME LEFT

112 days

Conclusion of a non-exclusive discount agreement according to § 130a para. 8 SGB V for the active ingredient Bimekizumab, ATC L04AC21 for the period 01.10.2026 - 31.03.2027

DAK-Gesundheit·Ref T-1443689617·via Bekanntmachungsservice

VALUE

€1

DEADLINE

Feb 5, 2027

TIME LEFT

117 days

Open-house drug discount agreements according to § 130a para. 8c SGB V for the KV region Berlin

AOK Nordost. Die Gesundheitskasse.·Ref T-104697664·via Bekanntmachungsservice

VALUE

--

DEADLINE

Feb 21, 2027

TIME LEFT

133 days

Open-house drug discount agreements according to § 130a para. 8c SGB V for the KV region Mecklenburg-Vorpommern

AOK Nordost. Die Gesundheitskasse.·Ref T-945347902·via Bekanntmachungsservice

VALUE

--

DEADLINE

Feb 21, 2027

TIME LEFT

133 days

Open-house drug discount agreements according to § 130a para. 8c SGB V for the KV region Brandenburg

AOK Nordost. Die Gesundheitskasse.·Ref T-807951360·via Bekanntmachungsservice

VALUE

--

DEADLINE

Feb 21, 2027

TIME LEFT

133 days

Open-house discount agreements 2025-01

Techniker Krankenkasse·Ref T-2091310200·via Bekanntmachungsservice

VALUE

--

DEADLINE

Feb 28, 2027

TIME LEFT

140 days

Open House Discount Contracts 2025-02

Techniker Krankenkasse·Ref T-63199494·via Bekanntmachungsservice

VALUE

--

DEADLINE

Mar 31, 2027

TIME LEFT

171 days

Conclusion not excl. drug rebate agreements according to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Oxycodone/Naloxone (WHO ATC code: N02AA55)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-1384841192·via Bekanntmachungsservice

VALUE

--

DEADLINE

Mar 31, 2027

TIME LEFT

171 days

Open house drug discount contracts for the active ingredient Ticagrelor, ATC B01AC24

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Ref T-367233372·via Bekanntmachungsservice

VALUE

--

DEADLINE

Mar 31, 2027

TIME LEFT

171 days

Open house discount contracts for the active ingredient Oxycodone and Naloxone, ATC N02AA55

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Ref T-1101286360·via Bekanntmachungsservice

VALUE

--

DEADLINE

Apr 30, 2027

TIME LEFT

201 days

Open house discount agreements for the active ingredient Axitinib, ATC L01EK01

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Ref T-1126177153·via Bekanntmachungsservice

VALUE

--

DEADLINE

Apr 30, 2027

TIME LEFT

201 days

Conclusion of non-exclusive drug rebate agreements according to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Denosumab Prolia (WHO ATC code: M05BX04)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-1154409128·via Bekanntmachungsservice

VALUE

--

DEADLINE

May 31, 2027

TIME LEFT

232 days

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredient Liraglutide (ATC code according to WHO: A10BJ02; official ATC: A10BJ02)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-233374321·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jun 30, 2027

TIME LEFT

262 days

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredients Formoterol/Aclidinium bromide (ATC code according to WHO: R03AL05)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-1085737393·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jun 30, 2027

TIME LEFT

262 days

Open House Biologika Discount Agreements 2026 - 15 Ranibizumab

Techniker Krankenkasse·Ref T-415107564·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jun 30, 2027

TIME LEFT

262 days

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredient Nilotinib (ATC code according to WHO: L01EA03)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-978534921·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jul 31, 2027

TIME LEFT

293 days

Open House Biologics Discount Contracts 2026-21 - Golimumab

Techniker Krankenkasse·Ref T-1745645260·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jul 31, 2027

TIME LEFT

293 days

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredient Ustekinumab (ATC code according to WHO: L04AC05)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Ref T-1302330612·via Bekanntmachungsservice

VALUE

--

DEADLINE

Jul 31, 2027

TIME LEFT

293 days

Medical Equipment

Medical Equipment

MRTs Fulda Clinic

Delivery of perfusors and holders

First aid emergency equipment (initial and subsequent supply) for the Baden-Württemberg Police

Open House Original Discount Contracts 2025-05 - Emtricitabine/Tenofovir disoproxil/Rilpivirine (drug combination)

Open-House-Biologika-Discount-Contracts 2025-25 - Aflibercept (ATC: S01LA05; Strength: 40 mg/ml)

Open House Original Discount Contracts 2025-19 - Tafamidis

Open house drug discount contracts for the active ingredient Dimethyl Fumarate, ATC L04AX07

Conclusion of a non-exclusive discount agreement according to § 130a para. 8 SGB V for the active ingredient Bimekizumab, ATC L04AC21 for the period 01.10.2026 - 31.03.2027

Open-house drug discount agreements according to § 130a para. 8c SGB V for the KV region Berlin

Open-house drug discount agreements according to § 130a para. 8c SGB V for the KV region Mecklenburg-Vorpommern

Open-house drug discount agreements according to § 130a para. 8c SGB V for the KV region Brandenburg

Open-house discount agreements 2025-01

Open House Discount Contracts 2025-02

Conclusion not excl. drug rebate agreements according to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Oxycodone/Naloxone (WHO ATC code: N02AA55)

Open house drug discount contracts for the active ingredient Ticagrelor, ATC B01AC24

Open house discount contracts for the active ingredient Oxycodone and Naloxone, ATC N02AA55

Open house discount agreements for the active ingredient Axitinib, ATC L01EK01

Conclusion of non-exclusive drug rebate agreements according to § 130a para. 8 SGB V by means of an open-house model for the active ingredient Denosumab Prolia (WHO ATC code: M05BX04)

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredient Liraglutide (ATC code according to WHO: A10BJ02; official ATC: A10BJ02)

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredients Formoterol/Aclidinium bromide (ATC code according to WHO: R03AL05)

Open House Biologika Discount Agreements 2026 - 15 Ranibizumab

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredient Nilotinib (ATC code according to WHO: L01EA03)

Open House Biologics Discount Contracts 2026-21 - Golimumab

Conclusion of non-exclusive drug discount agreements according to § 130a para. 8 SGB V using an open-house model for the active ingredient Ustekinumab (ATC code according to WHO: L04AC05)